Journal
EUROPEAN JOURNAL OF NEUROLOGY
Volume 16, Issue 3, Pages 424-426Publisher
WILEY-BLACKWELL PUBLISHING, INC
DOI: 10.1111/j.1468-1331.2008.02519.x
Keywords
glatiramer acetate; interferon-beta; multiple sclerosis; natalizumab; treatment failure
Categories
Ask authors/readers for more resources
Natalizumab has been recommended for the treatment of patients with relapsing remitting multiple sclerosis with insufficient response to interferon-beta (IFN-beta) or glatiramer acetate (GA). Prospective, observational study. We found a reduction of the annualized relapse rate from 2.1 under IFN-beta or GA to 0.2 one year after switching to natalizumab. There were 94% fewer gadolinium enhancing lesions with natalizumab. Natalizumab reduced short term clinical and MRI activity in second line therapy and efficacy is comparable to first line therapy as demonstrated in the pivotal trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available